The Manufacturers Life Insurance Company Makes New Investment in Rapport Therapeutics, Inc. $RAPP

Posted by on Sep 2nd, 2026

The Manufacturers Life Insurance Company bought a new stake in Rapport Therapeutics, Inc. (NASDAQ:RAPP – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 69,682 shares of the company’s stock, valued at approximately $2,904,000. The Manufacturers Life Insurance Company owned 0.15% of Rapport Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. TRV GP V LLC purchased a new stake in Rapport Therapeutics in the 2nd quarter worth about $261,709,477. Goldman Sachs Group Inc. grew its stake in shares of Rapport Therapeutics by 23.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock valued at $91,077,000 after buying an additional 579,903 shares during the last quarter. BlackRock Inc. bought a new position in shares of Rapport Therapeutics during the second quarter valued at approximately $112,500,000. Vanguard Group Inc. raised its holdings in shares of Rapport Therapeutics by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock worth $55,151,000 after buying an additional 191,219 shares during the period. Finally, Johnson & Johnson bought a new stake in shares of Rapport Therapeutics during the 2nd quarter worth approximately $74,360,823.

Insiders Place Their Bets

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 18,921 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $49.57, for a total transaction of $937,913.97. Following the completion of the sale, the chief executive officer owned 467,187 shares in the company, valued at $23,158,459.59. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 73,034 shares of company stock worth $3,484,157 in the last ninety days. 12.48% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on RAPP shares. UBS Group reiterated a “strong-buy” rating on shares of Rapport Therapeutics in a research report on Monday, August 17th. Citigroup reiterated a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. Raymond James Financial restated a “strong-buy” rating and issued a $75.00 target price on shares of Rapport Therapeutics in a research note on Monday, August 17th. HC Wainwright lifted their price target on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, William Blair assumed coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $62.86.

Get Our Latest Stock Report on Rapport Therapeutics

Rapport Therapeutics Stock Performance

NASDAQ RAPP opened at $48.56 on Wednesday. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -15.97 and a beta of 1.02. The company’s 50-day simple moving average is $43.80 and its two-hundred day simple moving average is $37.23. Rapport Therapeutics, Inc. has a one year low of $14.11 and a one year high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Equities analysts expect that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

About Rapport Therapeutics

(Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

Featured Articles

Want to see what other hedge funds are holding RAPP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rapport Therapeutics, Inc. (NASDAQ:RAPP – Free Report).

Institutional Ownership by Quarter for Rapport Therapeutics (NASDAQ:RAPP)

Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.